^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Anniko (penpulimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    Interim report from a phase 2 multicenter study of anti-PD-1 antibody (penpulimab) plus lenalidomide, rituximab, gemcitabine and oxaliplatin in Relapsed/ Refractory DLBCL

    Published date:
    06/09/2023
    Excerpt:
    Among the 7 patients with TP53 mutation who completed the induction therapy, 4 patients (57.1%) achieved CR….Preliminary results of this study show that penpulimab plus R2-GemOx demonstrated promising antitumor activity with manageable toxicities as a salvage treatment for R/R DLCBL.
    Secondary therapy:
    GemOx
    DOI:
    https://doi.org/10.1002/hon.3164_327
    Trial ID:
    NCT05186558